Alpha-1A adrenergic receptor
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Alpha-1A adrenergic receptor as ChEMBL target CHEMBL4892, mapped to UniProt P18130. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Alpha-1A adrenergic receptor matters
Alpha-1A adrenergic receptor is reviewed as Alpha-1A adrenergic receptor (UniProt P18130); the current evidence base includes 18 approved drugs, 252 compounds, and 38 assays, with lead potency reaching pChEMBL 10.5.
Alpha-1A adrenergic receptor Sequence length is 466 aa.
Review this target as Alpha-1A adrenergic receptor, mapped to UniProt P18130. Sequence length is 466 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 18 approved drugs, 252 compounds, and 38 assays for this target. The dominant activity type is KI. CHEMBL324090 is the current potency anchor at pChEMBL 10.5.
Use CHEMBL324090 as the tractability anchor when discussing potency (pChEMBL 10.5).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Alpha-1A adrenergic receptor matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P18130, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL324090
|
10.5 | Ki | Clinical |
|
|
No preferred name
CHEMBL1259217
|
10.2 | Ki | — |
|
|
No preferred name
CHEMBL91278
|
10.1 | Ki | — |
|
|
No preferred name
CHEMBL1259113
|
10.1 | Ki | — |
|
|
No preferred name
CHEMBL1258988
|
10.1 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ALFUZOSIN
CHEMBL709
|
2003 |
|
|
DEXMEDETOMIDINE
CHEMBL778
|
1999 |
|
|
TAMSULOSIN
CHEMBL836
|
1997 |
|
|
SERTINDOLE
CHEMBL12713
|
1996 |
|
|
TIZANIDINE
CHEMBL1079
|
1996 |
|
|
CLOZAPINE
CHEMBL42
|
1989 |
|
|
TERAZOSIN
CHEMBL611
|
1987 |
|
|
OXYMETAZOLINE
CHEMBL762
|
1986 |
|
|
PRAZOSIN
CHEMBL2
|
1976 |
|
|
CLONIDINE
CHEMBL134
|
1974 |
|
|
HALOPERIDOL
CHEMBL54
|
1967 |
|
|
PHENTOLAMINE
CHEMBL597
|
1952 |
|
|
PHENYLEPHRINE
CHEMBL1215
|
1952 |
|
|
NOREPINEPHRINE
CHEMBL1437
|
1950 |
|
|
MIANSERIN
CHEMBL6437
|
— |